Skip to main content

Table 1 Patients’ demographics at diagnosis

From: Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy

 

Total (n=158)

Seminoma (n=118)

Nonseminoma (n=40)

P value seminoma vs nonseminoma

age [y.o.]

37.0 ± 10.6

39.0 ± 9.8

31.2 ± 11.1

<0.01*

mean ± SD (range)

(1–65)

(22–65)

(1–54)

side n(%) right

91 (57.6%)

70 (59.3%)

21 (52.5%)

0.45

left

67 (42.4%)

48 (40.7%)

19 (47.5%)

tumor size [cm]

6.0 ± 2.7

6.4 ± 2.8

4.8 ± 1.9

<0.01

mean ± SD (range)

(1.5–18)

(1.5–18)

(2.0–9.0)

pT n(%) T1

48 (30.4%)

32 (27.1%)

16 (40.0%)

0.51

T2

63 (39.9%)

48 (40.7%)

15 (37.5%)

T3

2 (1.3%)

2 (1.7%)

0 (0%)

T4

1 (0.6%)

1 (0.8%)

0 (0%)

Tx

44 (27.8%)

35 (29.7%)

9 (22.5%)

LDH (IL/l)

449.8 ± 453.5

491.9 ± 504.9

323.6 ± 197.6

0.05

mean ± SD (range)

(121–3043)

(112–3043)

(121–945)

AFP (ng/ml)

124.0 ± 801.7

2.9 ± 1.4

474.1 ± 1544.0

<0.01

mean ± SD (range)

(1.0–9363.1)

(1.0–8.2)

(2.5–9363.1)

hCGβ (ng/ml)

1.0 ± 1.8

0.9 ± 1.8

1.2 ± 1.7

0.37

mean ± SD (range)

(<0.1–10.9)

(<0.1–10.9)

(<0.1–6.69)

 
  1. LDH, lactate dehydrogenase; AFP, α-fetoprotein, hCGβ, human chorionic gonadotropin β subunit.